Pasithea Therapeutics (KTTA) Divestments (2022 - 2023)
Pasithea Therapeutics (KTTA) posted Divestments of $319618.0 for Q2 2023, up 7529.94% sequentially from $4189.0 in Q1 2023, and up 173.94% YoY from $116676.2 in Q2 2022.
Pasithea Therapeutics (KTTA) Divestments (2022 - 2023) Analysis & Trends
Pasithea Therapeutics has reported Divestments for 2 years, with the latest figure at $319618.0 in Q2 2023.
- Quarterly Divestments rose 173.94% year-over-year to $319618.0 in Q2 2023, while the trailing twelve-month figure through Dec 2023 was $323807.0 (up 151.65% YoY) and the FY2023 annual result came in at $323807.0, up 151.65% from the prior year.
- Divestments grew to $319618.0 in Q2 2023 per KTTA's latest filing, from $4189.0 in the prior quarter.
- Over five years, Divestments peaked at $319618.0 in Q2 2023 and troughed at -$432291.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - | -13.21 Mn |
| 10 | Pasithea Therapeutics | 15.94 Mn | 15.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 319,618.00 |
| Mar 31, 2023 | 4,189.00 |
| Dec 31, 2022 | 71,892.00 |
| Sep 30, 2022 | -159,955.00 |
| Jun 30, 2022 | -432,291.00 |
| Mar 31, 2022 | -106,544.00 |